GlaxoSmithKline Produces World's First Malaria Vaccine

GlaxoSmithKline (NYSE:GSK) and the PATH Malaria Vaccine Initiative have developed the first licensed human malaria vaccine. The shot, called Mosquirix, has been recommended as safe and effective to use on babies in Africa.
According to an article from Reuters:
Mosquirix, also known as RTS,S and part-funded by the Bill & Melinda Gates Foundation, will now be assessed by the World Health Organization (WHO), which said on Friday it would begin a review in October on when and where it could be used. The WHO aims to make a recommendation by November.
Mosquirix was assessed for quality, safety and efficacy under a special procedure that allows the EMA to evaluate a product even if it will not be marketed in the European Union.
Beyond the WHO’s November recommendation, Mosquirix would still have to be reviewed by national regulatory authorities in any country wishing to use it. The WHO’s Hartl said this meant it is unlikely to be rolled out anywhere until at least 2017.
Click here to read the full article from Reuters.